RCUS — Arcus Biosciences Inc. stock price and chart

Share this page

RCUS

$22.12-3.07%

as of close, Oct 16, 2026

☾ AH $22.12 -3.07%

Arcus Biosciences Inc.Stock · HealthcareRussell 2000 0.09%US Stock Market 0.004%Russell 3000 0.003%

PeersMRNALLYMDTUNHJNJTMO

Technical analysis2

Overlay lines0

Addendum charts0

Available history since Mar 21, 2018

VolumeEEEE

20182020202220242026

10.015.020.025.030.035.040.045.0010.0M20.0M$22.12

2026-10-16

Price$22.12

MA20$26.86

MA50$24.09

Vol6.6M

What would $1,000 invested in RCUS be worth today? →

RCUS returns: By year · By month · By week · Trailing

Key stats#

Price data

Price: $22.12
YTD price return: -7.18%
YTD total return: -7.18%
Next earnings: Oct 27, 2026
Market cap: 2.8B2018-03 63.2M2026-10 2.8B+4357.2% over the window
Enterprise value: 2.9B
Shares outstanding: 127.3M2017-12 4.1M2026-06 127.3M+3012.6% over the window
52W low: $16.04
52W high: $31.74
From 52W high: -30.30%
From 52W low: +37.91%
52W range: 39%

Volume

Rel volume: 0.88×
30D volume: 1.6M
30D $ vol: 40.6M

Fundamentals

Sales (ttm): 117M2017-12 1.4M2026-06 117M+8180.3% over the window
Sales/share: $0.922017-12 $0.352026-06 $0.92+166.0% over the window
EPS (ttm): -$3.862019-09 -$1.832026-06 -$3.86+111.0% over the window
FCF (ttm): -475M2016-12 -17M2026-06 -475M+2687.1% over the window
FCF/share: -$3.732017-12 -$7.472026-06 -$3.73-50.1% over the window
Book value/share: $3.642017-12 -$17.682026-06 $3.64-120.6% over the window
Net margin: -393.16%2017-12 -3756.7%2026-06 -393.2%-89.5% over the window
ROE: -99.14%2018-03 -22.1%2026-06 -99.1%+349.2% over the window
ROA: -49.78%2017-12 -27.9%2026-06 -49.8%+78.6% over the window
Debt / equity: 0.22×2023-12 0.002026-06 0.22
Current ratio: 3.822017-12 13.902026-06 3.82-72.5% over the window

Growth (CAGR, ttm) · 10Y

Sales: -55.37%2025-06-30 → 2026-06-30262M → 117M (-55.3% total)+35.52%2023-06-30 → 2026-06-3047M → 117M (+148.9% total)+4.71%2021-06-30 → 2026-06-3092.9M → 117M (+25.9% total)n/a
Shares: +19.65%2025-06-30 → 2026-06-30106.4M → 127.3M (+19.6% total)+19.56%2023-06-30 → 2026-06-3074.5M → 127.3M (+70.9% total)+12.27%2021-06-30 → 2026-06-3071.4M → 127.3M (+78.4% total)n/a

Per-share growth (CAGR, ttm) · 10Y

Sales/share: -62.70%2025-06-30 → 2026-06-30$2.46 → $0.92 (-62.7% total)+13.35%2023-06-30 → 2026-06-30$0.63 → $0.92 (+45.7% total)-6.73%2021-06-30 → 2026-06-30$1.30 → $0.92 (-29.4% total)n/a
Book value/share: -29.37%2025-06-30 → 2026-06-30$5.16 → $3.64 (-29.4% total)-21.72%2023-06-30 → 2026-06-30$7.60 → $3.64 (-52.0% total)-15.52%2021-06-30 → 2026-06-30$8.47 → $3.64 (-57.0% total)n/a
Price: +33.28%2025-10-16 → 2026-10-16$16.60 → $22.12 (+33.3% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.+10.60%2023-10-16 → 2026-10-16$16.35 → $22.12 (+35.3% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.-8.44%2021-10-15 → 2026-10-16$34.39 → $22.12 (-35.7% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.n/a
Total return: +33.28%2025-10-16 → 2026-10-16$16.60 → $22.12 (+33.3% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.+10.60%2023-10-16 → 2026-10-16$16.35 → $22.12 (+35.3% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.-8.44%2021-10-15 → 2026-10-16$34.39 → $22.12 (-35.7% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.n/a

Fundamentals end at the last reported quarter; price and total return end at the latest close.

Valuation

P/E (ttm)Price ÷ TTM diluted EPS. Net income carries everything below the operating line, including one-off gains. Negative when the trailing year lost money.: -5.7×2018-03 -1.192026-10 -6.12+414.3% over the window
Fwd P/E: -7.4×
P/S (ttm)Market cap ÷ TTM revenue.: 24.1×2018-03 44.702026-10 24.06-46.2% over the window
P/B (mrq)Market cap ÷ stockholders' equity at the most recent quarter end.: 6.1×2018-03 -0.872026-10 6.07-794.8% over the window
EV/Sales (ttm): 24.5×
FCF yield (ttm)TTM free cash flow ÷ market cap — the inverse of P/FCF.: -16.86%2017-12 -48.4%2026-06 -12.1%-75.0% over the window
Buyback yield (realized, 1y)1 − shares_at(2026-06-30) ÷ shares_at(2025-06-30) = 1 − 127.3M ÷ 106.4M. Point-in-time share counts from the company's own SEC filings (the same count at both ends), published only when the cash flow statement shows repurchases inside that window. A falling price can't inflate it; negative means net dilution.: -19.65%
Shareholder yield (realized, 1y)Buyback leg + dividend leg: shares retired over the year (-19.65%) + dividends paid over that year ($0) ÷ market_cap_at(2025-06-30) ($866.3M). Both legs are measured against the start of the window, so a payout can't shrink its own denominator.: -19.65%
Buyback yield (cash, ttm)Buybacks net of issuance over the trailing twelve months ($-287M) ÷ today's market cap ($2.8B). Dollars SPENT over what the company is worth NOW — a stock that fell after buying reads high.: -10.19%2017-12 0.0%2026-06 -7.3%
Shareholder yield (cash, ttm)(TTM buybacks net of issuance $-287M + TTM dividends $0) ÷ today's market cap ($2.8B). Same caveat as the cash buyback yield.: -10.19%2017-12 0.0%2026-06 -7.3%

Vs own 10Y history

P/S: 36th
P/B: 93rd

Bar = where today’s multiple sits in RCUS’s own 10-year range:near a decade-low (cheap)→near a decade-high (rich).

Performance · price return · as of 2026-10-16#

-3.07%

-9.38%

-10.26%

-16.97%

YTD

-7.18%

+33.25%

-35.68%

Financial statements

Open full RCUS financials →

Loading financial statements…

Ticker	Name	1M	1D
LLY	Eli Lilly and Company	+10.48%	+0.43%
JNJ	Johnson & Johnson	-4.38%	+0.90%
ABBV	AbbVie Inc.	+8.73%	+0.71%
UNH	UnitedHealth Group Incorporated Common Stock (DE)	+6.97%	-1.29%
MRK	Merck & Co. Inc.	+0.72%	+0.52%
NVS	Novartis AG	+8.59%	+0.16%
TMO	Thermo Fisher Scientific Inc.	+6.41%	-0.93%
AMGN	Amgen Inc.	+14.92%	-0.35%

RCUS — Arcus Biosciences Inc. price, chart and key statistics